Skip to main content

Drug Interactions between Plavix and zafirlukast

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

zafirlukast clopidogrel

Applies to: zafirlukast and Plavix (clopidogrel)

In vitro studies have shown that high concentrations of clopidogrel inhibit CYP450 2C9 isoenzymes. The metabolism of drugs which are substrates for this enzyme may be decreased, potentiating toxicity of the substrate drug. The clinical significance and magnitude of this interaction is not known. Dose adjustments may be necessary if an interaction is suspected.

References (1)
  1. (2001) "Product Information. Plavix (clopidogrel)." Bristol-Myers Squibb

Drug and food interactions

Moderate

zafirlukast food

Applies to: zafirlukast

ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of zafirlukast. In two separate studies, one using a high-fat and the other a high-protein meal, administration of zafirlukast with food reduced the mean bioavailability by approximately 40%.

MANAGEMENT: To ensure maximal oral absorption, zafirlukast should be administered at least 1 hour before or 2 hours after meals.

References (1)
  1. (2001) "Product Information. Accolate (zafirlukast)." Astra-Zeneca Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer